Ginwa Enterprise Group Inc - Asset Resilience Ratio
Ginwa Enterprise Group Inc (600080) has an Asset Resilience Ratio of 6.26% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600080 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1994–2025)
This chart shows how Ginwa Enterprise Group Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 600080 asset base.
Liquid Assets Composition Over Time
This chart breaks down Ginwa Enterprise Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Ginwa Enterprise Group Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥122.81 Million | 6.26% |
| Total Liquid Assets | CN¥122.81 Million | 6.26% |
Asset Resilience Insights
- Limited Liquidity: Ginwa Enterprise Group Inc maintains only 6.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ginwa Enterprise Group Inc Industry Peers by Asset Resilience Ratio
Compare Ginwa Enterprise Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Ginwa Enterprise Group Inc (1994–2025)
The table below shows the annual Asset Resilience Ratio data for Ginwa Enterprise Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.56% | CN¥49.28 Million ≈ $7.21 Million |
CN¥1.93 Billion ≈ $282.12 Million |
+1.29pp |
| 2024-12-31 | 1.27% | CN¥25.02 Million ≈ $3.66 Million |
CN¥1.97 Billion ≈ $288.58 Million |
-1.43pp |
| 2023-12-31 | 2.70% | CN¥56.83 Million ≈ $8.32 Million |
CN¥2.11 Billion ≈ $308.55 Million |
-4.66pp |
| 2022-12-31 | 7.35% | CN¥145.14 Million ≈ $21.24 Million |
CN¥1.97 Billion ≈ $288.92 Million |
-18.86pp |
| 2021-12-31 | 26.21% | CN¥490.18 Million ≈ $71.73 Million |
CN¥1.87 Billion ≈ $273.67 Million |
+9.69pp |
| 2020-12-31 | 16.52% | CN¥323.58 Million ≈ $47.35 Million |
CN¥1.96 Billion ≈ $286.60 Million |
+12.02pp |
| 2019-12-31 | 4.50% | CN¥89.18 Million ≈ $13.05 Million |
CN¥1.98 Billion ≈ $289.71 Million |
+4.41pp |
| 2018-12-31 | 0.09% | CN¥1.78 Million ≈ $260.12K |
CN¥1.97 Billion ≈ $288.98 Million |
-0.26pp |
| 2017-12-31 | 0.35% | CN¥4.93 Million ≈ $720.75K |
CN¥1.42 Billion ≈ $207.66 Million |
-1.27pp |
| 2016-12-31 | 1.62% | CN¥23.37 Million ≈ $3.42 Million |
CN¥1.44 Billion ≈ $211.30 Million |
-1.07pp |
| 2015-12-31 | 2.69% | CN¥33.78 Million ≈ $4.94 Million |
CN¥1.26 Billion ≈ $184.10 Million |
-8.72pp |
| 2014-12-31 | 11.41% | CN¥144.50 Million ≈ $21.14 Million |
CN¥1.27 Billion ≈ $185.37 Million |
+11.38pp |
| 2005-12-31 | 0.02% | CN¥525.66K ≈ $76.92K |
CN¥2.29 Billion ≈ $334.63 Million |
-0.01pp |
| 2004-12-31 | 0.03% | CN¥567.42K ≈ $83.03K |
CN¥1.85 Billion ≈ $271.44 Million |
-0.10pp |
| 2003-12-31 | 0.13% | CN¥1.90 Million ≈ $278.03K |
CN¥1.46 Billion ≈ $214.23 Million |
0.00pp |
| 2002-12-31 | 0.13% | CN¥1.74 Million ≈ $255.26K |
CN¥1.33 Billion ≈ $195.08 Million |
-23.46pp |
| 2000-12-31 | 23.59% | CN¥244.00 Million ≈ $35.70 Million |
CN¥1.03 Billion ≈ $151.37 Million |
+12.52pp |
| 1996-12-31 | 11.07% | CN¥18.00 Million ≈ $2.63 Million |
CN¥162.65 Million ≈ $23.80 Million |
-1.99pp |
| 1995-12-31 | 13.05% | CN¥5.20 Million ≈ $760.92K |
CN¥39.83 Million ≈ $5.83 Million |
+3.71pp |
| 1994-12-31 | 9.34% | CN¥2.20 Million ≈ $321.93K |
CN¥23.54 Million ≈ $3.45 Million |
-- |
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more